[Prevention of venous thromboembolic complications in patients with ulcerative colitis].

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Terapevticheskii Arkhiv Pub Date : 2025-03-26 DOI:10.26442/00403660.2025.02.203120

A A Lishchinskaya, O V Knyazev, A V Kagramanova, N A Fadeeva, G A Dudina, M Y Timanovskaya, K K Noskova, A I Рarfenov

{"title":"[Prevention of venous thromboembolic complications in patients with ulcerative colitis].","authors":"A A Lishchinskaya, O V Knyazev, A V Kagramanova, N A Fadeeva, G A Dudina, M Y Timanovskaya, K K Noskova, A I Рarfenov","doi":"10.26442/00403660.2025.02.203120","DOIUrl":null,"url":null,"abstract":"Background: The incidence of venous thromboembolic complications (VTEC) in patients with inflammatory bowel diseases is approximately 3 times higher than in the general population and leads to a 2-fold increase in the risk of mortality. The risk of VTEC is the highest during the patient's hospital stay.Aim: To compare the overall VTEC risk in inpatients with ulcerative colitis (UC) with and without VTEC primary prevention.Materials and methods: In 2020, anticoagulant therapy was used for patients with UC in the case of acute venous thrombosis, and in 2022, primary thromboprophylaxis in patients with UC with moderate and high VTEC risk was based on the data obtained from the previous analysis of VTEC risk factors in inpatients with inflammatory bowel diseases. VTEC prophylaxis in UC patients was performed with a low molecular weight heparin (LMWH) - calcium nadroparin - at a dose of 0.3 mL (2850 IU anti-Xa) per day subcutaneously throughout the stay in the round-the-clock hospital.Results: In 2020, venous thrombosis was diagnosed in 16 (1.8%) patients with UC, including venous thrombosis of the lower extremities in 3 (0.3%) patients, venous thrombosis of the upper extremities in 7 (0.8%), pulmonary embolism in 2 (0.2%), and combined thrombosis in 4 (0.5%). In 2022, venous thrombosis was diagnosed in 5 (0.5%) patients with UC, including venous thrombosis of the lower extremities in 1 (0.1%) patient, venous thrombosis of the upper extremities in 3 (0.3%), and pulmonary embolism in 1 (0.1%). Thus, primary prevention with an LMWH significantly reduces the risk of VTEC in hospitalized patients with UC (relative risk 0.285, 95% confidence interval 0.103-0.774; χ2=6.917; p=0.009).Conclusion: Our results demonstrate that primary prevention with an LMWH significantly reduces the risk of VTEC in patients with UC hospitalized in a round-the-clock hospital.","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"128-136"},"PeriodicalIF":0.3000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Terapevticheskii Arkhiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2025.02.203120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The incidence of venous thromboembolic complications (VTEC) in patients with inflammatory bowel diseases is approximately 3 times higher than in the general population and leads to a 2-fold increase in the risk of mortality. The risk of VTEC is the highest during the patient's hospital stay.

Aim: To compare the overall VTEC risk in inpatients with ulcerative colitis (UC) with and without VTEC primary prevention.

Materials and methods: In 2020, anticoagulant therapy was used for patients with UC in the case of acute venous thrombosis, and in 2022, primary thromboprophylaxis in patients with UC with moderate and high VTEC risk was based on the data obtained from the previous analysis of VTEC risk factors in inpatients with inflammatory bowel diseases. VTEC prophylaxis in UC patients was performed with a low molecular weight heparin (LMWH) - calcium nadroparin - at a dose of 0.3 mL (2850 IU anti-Xa) per day subcutaneously throughout the stay in the round-the-clock hospital.

Results: In 2020, venous thrombosis was diagnosed in 16 (1.8%) patients with UC, including venous thrombosis of the lower extremities in 3 (0.3%) patients, venous thrombosis of the upper extremities in 7 (0.8%), pulmonary embolism in 2 (0.2%), and combined thrombosis in 4 (0.5%). In 2022, venous thrombosis was diagnosed in 5 (0.5%) patients with UC, including venous thrombosis of the lower extremities in 1 (0.1%) patient, venous thrombosis of the upper extremities in 3 (0.3%), and pulmonary embolism in 1 (0.1%). Thus, primary prevention with an LMWH significantly reduces the risk of VTEC in hospitalized patients with UC (relative risk 0.285, 95% confidence interval 0.103-0.774; χ²=6.917; p=0.009).

Conclusion: Our results demonstrate that primary prevention with an LMWH significantly reduces the risk of VTEC in patients with UC hospitalized in a round-the-clock hospital.

查看原文本刊更多论文

溃疡性结肠炎患者静脉血栓栓塞并发症的预防

背景：炎症性肠病患者的静脉血栓栓塞并发症（VTEC）发生率约为普通人群的3倍，导致死亡风险增加2倍。在病人住院期间，VTEC的风险最高。目的：比较有无VTEC一级预防的溃疡性结肠炎（UC）住院患者的总体VTEC风险。材料与方法：2020年对急性静脉血栓形成的UC患者进行抗凝治疗，2022年对中高VTEC风险的UC患者进行初级血栓预防，基于之前对炎症性肠病住院患者VTEC危险因素分析获得的数据。UC患者的VTEC预防采用低分子肝素(LMWH) -钠氧化钙-在整个24小时住院期间每天皮下注射0.3 mL （2850 IU抗xa）。结果：2020年，UC患者中有16例（1.8%）诊断为静脉血栓形成，其中下肢静脉血栓3例（0.3%），上肢静脉血栓7例（0.8%），肺栓塞2例（0.2%），合并血栓4例（0.5%）。2022年，5例（0.5%）UC患者被诊断为静脉血栓形成，其中1例下肢静脉血栓形成（0.1%），3例上肢静脉血栓形成（0.3%），1例肺栓塞（0.1%）。因此，低分子肝素一级预防可显著降低UC住院患者VTEC的风险(相对风险0.285,95%可信区间0.103-0.774；χ2 = 6.917;p = 0.009)。结论：我们的研究结果表明，低分子肝素一级预防可显著降低在24小时医院住院的UC患者发生VTEC的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Terapevticheskii Arkhiv 医学-医学：内科

CiteScore

1.40

自引率

33.30%

发文量

171

审稿时长

3-8 weeks

期刊介绍： Терапевтический архив The journal was founded by the prominent Russian therapists M.P. Konchalovsky and G.F. Lang in 1923. Then its editors-in-chief were Professors V.N. Vinogradov and A.G. Gukasyan. Since 1972, E.I. Chazov, Academician of the Russian Academy of Sciences, has been heading the editorial board of the journal. Over 90 years, there have been more than 1000 issues where the authors and editorial staff have done their best for readers to keep abreast of current advances in medical science and practice and for physicians to master the advanced principles of recognition and treatment of a wide spectrum of visceral diseases. The papers published in the journal (editorials, original articles, lectures, reviews, etc.) cover both current scientific achievements and practical experience in diagnosing, treating, and preventing visceral diseases. The authors of publications are not only Russian, but also foreign scientists and physicians. All papers are peer-reviewed by highly qualified Russian specialists. The journal is published monthly. Traditionally, each issue has predominantly certain thematic areas covering individual therapy specializations. Every year, one of the issues is devoted to related problems in practical medicine (allergology and immunology, neurology and psychiatry, obstetrics, oncology, etc.). This all draws the attention of the reading public to the journal. The journal is indexed in RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus/EMBASE, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich''s Periodicals Directory. The journal is included in the list of periodicals recommended by the Higher Attestation Committee for publishing the papers containing the basic materials of doctoral and candidate dissertations. By the decision of the Presidium of the Russian Academy of Medical Sciences, the “Therapevticheskiy Arkhiv” was awarded the Botkin medal. It was admitted to the European Association of Sciences Editors (EASE). The journal was honored with the Golden Press Fund decoration at the 13th International Press Professional Exhibition.